Menu
Washingtoner
  • Home
  • Business
  • Aerospace
  • Boeing
  • Construction
  • Transportation
  • Kelly Ortberg
  • Manufacturing
  • Crypto
Washingtoner

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
Washingtoner/10287890

Trending...
  • Kansas City Steak Company Shares the Return of Their Holiday Gift Box
  • Taikan's T-V856S VMC Earns Prestigious 2025 Vogel Global Pioneer Award
  • Dr. Jay A. Johannigman Delivers Lecture at the John R. Border Memorial Lectureship in Buffalo
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - Washingtoner -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on Washingtoner
  • Sweet Memories Vintage Tees Debuts Historic ORCA™ Beverage Nostalgic Soda Collection
  • UK Financial Ltd Celebrates Global Recognition as MayaCat (MCAT) Evolves Into SMCAT — The World's First Meme Coin Under ERC-3643 Compliance
  • U.S. Military to Benefit from Drone Tech Agreement with NovaSpark Energy, Plus Longer NASA Space Missions via Solar Power Leader: Ascent Solar $ASTI
  • $76 Million in Gold & Silver Holdings and Expanding Production — Pioneering the Future of Gold: Asia Broadband Inc. (Stock Symbol: AABB) is Surging
  • Wohler announces three SRT monitoring enhancements for its iVAM2-MPEG monitor and the addition of front panel PID selection of A/V/subtitle streams

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Seattle Bathroom Remodeling Announces Service Area Expansion to Greater Seattle Region
  • Taking on the Multi-Billion-Dollar Swipe Industry: AI Curates Who You Meet—IRL over brunch
  • Curated Domain Name Marketplace
  • Spokane: Suspect in Custody After Committing Multiple Armed Robberies
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion
  • Vet Maps Launches National Platform to Spotlight Veteran-Owned Businesses and Causes
  • $114.6 Million in Revenues, Up 54%: Uni-Fuels Holdings (N A S D A Q: UFG) Accelerates Global Expansion Across Major Shipping Hubs as Demand Surges
  • Dental Care Solutions Unveils New Website for Enhanced Patient Engagement
  • TradingHabits.com Launches to Support Day Trader Well-being
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • Fire Outside City of Tacoma Facility on Martin Luther King Jr. Way Temporarily Disrupts PEG Channels
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • BITE Data raises $3m to build AI tools for global trade compliance teams
  • Phinge Issues Notice of Possible Infringement, Investigates App-less AI Agents & Technology for Unauthorized Use of its Patented App-less Technologies
  • Tacoma: Homicide Investigation – 5100 S 58th Street
  • Huntington Learning Center of Russellville Marks 1 Year Anniversary; Extends Reduced Grant-Aligned Rates to All Students in Learning Center Services
  • CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress
  • purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
  • WHES Retains BloombergNEF Tier 1 Ranking for Sixth Consecutive Quarter
_catLbl0 _catLbl1

Popular on Washingtoner

  • New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them - 111
  • New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks - 110
  • Applicants Sought for the Tacoma Community Redevelopment Authority Board
  • Some Music for Donald's Bad Day
  • ExtraCarry Now Supports Taurus GX2 13-Round Mags and 15-Round Magazines
  • Tacoma: Mid-Biennium Budget Modification (Mid-Mod) Update Frequently Asked Questions
  • Oom Yung Doe Hosts Children's Halloween Safety Seminar in Kirkland
  • Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling
  • Hiclean Tools Releases HCX2100 Electric Pressure Washer
  • Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy

Similar on Washingtoner

  • November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC
  • Valeo Health Leads a New Era of Longevity and Preventive Health in the UAE
  • Sweet Memories Vintage Tees Debuts Historic ORCA™ Beverage Nostalgic Soda Collection
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion
  • Dental Care Solutions Unveils New Website for Enhanced Patient Engagement
  • TradingHabits.com Launches to Support Day Trader Well-being
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • Huntington Learning Center of Russellville Marks 1 Year Anniversary; Extends Reduced Grant-Aligned Rates to All Students in Learning Center Services
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute